Core Viewpoint - Nanwei Technology's stock has shown significant growth this year, with a 60.18% increase, indicating strong market performance and investor interest [1]. Group 1: Stock Performance - As of August 22, Nanwei Technology's stock price reached 28.09 CNY per share, with a market capitalization of 11.343 billion CNY [1]. - The stock has experienced a 3.27% increase over the last five trading days, a 2.41% increase over the last 20 days, and a 33.91% increase over the last 60 days [1]. - Year-to-date, the stock has appeared on the trading leaderboard once, with a net buy of -5.5156 million CNY on February 27 [1]. Group 2: Financial Performance - For the period from January to March 2025, Nanwei Technology reported a revenue of 189 million CNY, reflecting a year-on-year growth of 22.39% [2]. - The company has distributed a total of 115 million CNY in dividends since its A-share listing, with 86.8418 million CNY distributed over the past three years [2]. Group 3: Shareholder Information - As of March 31, 2025, the number of shareholders for Nanwei Technology was 14,800, a decrease of 0.99% from the previous period [2]. - The average number of circulating shares per shareholder increased by 1.00% to 27,351 shares [2]. - Among the top ten circulating shareholders, the China Europe Medical Health Mixed A fund is a new entrant, holding 8.6703 million shares [2].

Company Overview - Reap Bio is located in Tianjin Free Trade Zone and was established on August 2, 2001, with its listing date on September 17, 2010 [1] - The company specializes in veterinary biological products (animal vaccines) and chemical pharmaceuticals [1] Stock Performance - As of August 22, Reap Bio's stock price decreased by 2.01%, trading at 22.93 CNY per share, with a total market capitalization of 10.657 billion CNY [1] - Year-to-date, the stock price has increased by 26.85%, with a 0.66% rise over the last five trading days, a 4.61% increase over the last 20 days, and a 7.02% decline over the last 60 days [1] Financial Performance - For the period from January to March 2025, Reap Bio reported a revenue of 822 million CNY, representing a year-on-year growth of 54.09% [2] - The company has distributed a total of 1.371 billion CNY in dividends since its A-share listing, with 462 million CNY distributed over the last three years [2] Shareholder Information - As of August 8, the number of shareholders for Reap Bio was 27,000, with an average of 12,406 circulating shares per shareholder [2] - As of March 31, 2025, the fifth largest circulating shareholder is Harvest Agricultural Industry Stock A, holding 6.3889 million shares, an increase of 696,900 shares from the previous period [2] Market Activity - On August 22, the net outflow of main funds was 7.9021 million CNY, with large orders accounting for 15.94% of purchases and 21% of sales [1]

8月22日，固德威盘中上涨2.01%，截至10:14，报48.64元/股，成交1.29亿元，换手率1.11%，总市值117.99亿元。 截至3月31日，固德威股东户数1.69万，较上期减少4.02%；人均流通股14364股，较上期增加4.19%。2025年1月-3月，固德威实现营业收入18.82亿元，同比增长67.13%；归母净利润-2 分红方面，固德威A股上市后累计派现5.38亿元。近三年，累计派现3.27亿元。 机构持仓方面，截止2025年3月31日，固德威十大流通股东中，汇丰晋信低碳先锋股票A（540008）位居第六大流通股东，持股503.61万股，持股数量较上期不变。广发高端制造股票A（004 责任编辑：小浪快报 资金流向方面，主力资金净流入57.79万元，特大单买入484.08万元，占比3.75%，卖出521.92万元，占比4.04%；大单买入4365.38万元，占比33.82%，卖出4269.75万元，占比33.08% 固德威今年以来股价涨18.92%，近5个交易日跌2.72%，近20日涨11.94%，近60日涨23.73%。 资料显示，固德威技术股份有限公司位于江苏省苏州市高新区紫金路90号，成 ...

Company Overview - TeBao Bio is located in Xiamen, Fujian Province, established on August 7, 1996, and listed on January 17, 2020 [2] - The company specializes in recombinant proteins and long-acting drugs, classified under the pharmaceutical and biological industry, specifically in the bioproducts sector [2] Stock Performance - As of August 22, TeBao Bio's stock price decreased by 2.01%, trading at 84.47 CNY per share, with a market capitalization of 34.362 billion CNY [1] - Year-to-date, the stock price has increased by 16.11%, with a recent decline of 1.32% over the last five trading days, and an increase of 11.16% over the last 20 days [2] - The stock has shown a 4.46% increase over the last 60 days [2] Financial Performance - For the period from January to June 2025, TeBao Bio reported a revenue of 1.511 billion CNY, reflecting a year-on-year growth of 26.96% [2] - The company has distributed a total of 577 million CNY in dividends since its A-share listing, with 506 million CNY distributed over the past three years [2] Shareholder Information - As of June 30, 2025, the number of shareholders increased to 8,439, up by 13% from the previous period [2] - The average number of circulating shares per shareholder decreased by 11.51% to 48,204 shares [2] - Among the top ten circulating shareholders, Huaxia SSE Sci-Tech Innovation Board 50 ETF holds 8.9489 million shares, an increase of 837,500 shares compared to the previous period [2] Capital Flow - On August 22, the net inflow of main funds was 2.4143 million CNY, with large orders accounting for 20.80% of total purchases [1] - The total transaction volume reached 68.1594 million CNY, with a turnover rate of 0.20% [1]

截至7月31日，清溢光电股东户数1.03万，较上期增加4.55%；人均流通股26021股，较上期减少4.35%。2025年1月-3月，清溢光电实现营业收入2.99亿元，同比增长9.83%；归母净利润5 分红方面，清溢光电A股上市后累计派现1.89亿元。近三年，累计派现1.28亿元。 8月22日，清溢光电盘中上涨2.03%，截至09:38，报32.68元/股，成交1624.73万元，换手率0.19%，总市值102.88亿元。 资金流向方面，主力资金净流入197.70万元，特大单买入161.21万元，占比9.92%，卖出0.00元，占比0.00%；大单买入162.00万元，占比9.97%，卖出125.51万元，占比7.72%。 清溢光电今年以来股价涨43.77%，近5个交易日涨2.86%，近20日涨11.50%，近60日涨29.16%。 今年以来清溢光电已经1次登上龙虎榜，最近一次登上龙虎榜为1月17日，当日龙虎榜净买入2597.13万元；买入总计8762.67万元 ，占总成交额比15.08%；卖出总计6165.55万元 ，占总成 资料显示，深圳清溢光电股份有限公司位于广东省深圳市南山区朗山二路北清溢光电大楼，成 ...

Company Overview - Kasei Biotech Co., Ltd. is located at 396 Lane 11, Oasis Ring Road, Minhang District, Shanghai, established on November 24, 2000, and listed on August 12, 2020 [1] - The company specializes in synthetic biology and related fields, classified under the basic chemical industry, specifically in chemical products and other chemical products [1] Stock Performance - As of August 22, Kasei Biotech's stock price increased by 2.01%, reaching 51.70 CNY per share, with a trading volume of 64.04 million CNY and a turnover rate of 0.22%, resulting in a total market capitalization of 37.29 billion CNY [1] - Year-to-date, the stock price has risen by 34.63%, with a 5-day increase of 5.34%, a 20-day increase of 6.62%, and a 60-day increase of 9.67% [1] Financial Performance - For the period from January to June 2025, Kasei Biotech reported a revenue of 1.671 billion CNY, reflecting a year-on-year growth of 15.68% [2] - The company has distributed a total of 1.023 billion CNY in dividends since its A-share listing, with 503 million CNY distributed over the past three years [2] Shareholder Information - As of June 30, 2025, Kasei Biotech had 11,700 shareholders, a decrease of 2.87% from the previous period, with an average of 49,801 circulating shares per shareholder, an increase of 2.95% [2] - Among the top ten circulating shareholders, the Huaxia SSE Sci-Tech Innovation Board 50 ETF (588000) ranked as the eighth largest shareholder, holding 19.85 million shares, an increase of 3.46 million shares from the previous period [2]

Group 1 - The core viewpoint of the news is that Hongtian Co., Ltd. has experienced significant stock price fluctuations and trading activity, with a notable increase in stock price this year [1] - As of August 22, Hongtian's stock price rose by 2.01% to 51.33 CNY per share, with a total market capitalization of 10.677 billion CNY [1] - The company has seen a year-to-date stock price increase of 104.07%, with a 0.54% decline over the last five trading days, an 82.15% increase over the last 20 days, and a 116.28% increase over the last 60 days [1] Group 2 - As of March 31, the number of shareholders for Hongtian Co., Ltd. was 8,655, a decrease of 8.69% from the previous period [2] - The company reported a revenue of 135 million CNY for the first quarter of 2025, a year-on-year decrease of 59.91% [2] - Since its A-share listing, Hongtian has distributed a total of 302 million CNY in dividends, with 50.708 million CNY distributed over the last three years [2]

Company Overview - Guangxin Co., Ltd. is located in Guangde City, Anhui Province, established on March 15, 2000, and listed on May 13, 2015. The company specializes in the research and development of pesticides and intermediates using phosgene as a raw material [1][2]. Stock Performance - As of August 22, Guangxin's stock price decreased by 2.02%, trading at 12.11 CNY per share, with a total market capitalization of 11.023 billion CNY. The stock has seen a year-to-date increase of 2.80%, a decline of 1.54% over the last five trading days, a rise of 1.25% over the last 20 days, and a 9.10% increase over the last 60 days [1]. Financial Performance - For the first half of 2025, Guangxin reported a revenue of 1.890 billion CNY, representing a year-on-year decrease of 17.36%. The company has cumulatively distributed 2.503 billion CNY in dividends since its A-share listing, with 1.637 billion CNY distributed over the past three years [2]. Shareholder Information - As of June 30, 2025, Guangxin had 15,300 shareholders, a decrease of 20.11% from the previous period. The average number of circulating shares per shareholder increased by 25.17% to 59,393 shares [2]. Institutional Holdings - As of June 30, 2025, the third-largest circulating shareholder of Guangxin is the招商核心竞争力混合A fund, holding 22.4837 million shares, which is an increase of 7.8943 million shares compared to the previous period [2].

截至6月30日，常熟银行股东户数4.13万，较上期减少4.29%；人均流通股80392股，较上期增加14.93%。2025年1月-6月，常熟银行实现营业收入0.00元；归母净利润19.69亿元，同比增 分红方面，常熟银行A股上市后累计派现50.62亿元。近三年，累计派现21.24亿元。 资金流向方面，主力资金净流出1266.18万元，特大单买入1527.91万元，占比9.12%，卖出3333.82万元，占比19.91%；大单买入3616.61万元，占比21.59%，卖出3076.88万元，占比 常熟银行今年以来股价涨13.15%，近5个交易日跌1.18%，近20日跌0.66%，近60日涨8.13%。 资料显示，江苏常熟农村商业银行股份有限公司位于江苏省常熟市新世纪大道58号，成立日期2001年12月3日，上市日期2016年9月30日，公司主营业务涉及公司金融业务、个人金融业务、资 常熟银行所属申万行业为：银行-农商行Ⅱ-农商行Ⅲ。所属概念板块包括：低市盈率、社保重仓、中盘、融资融券、增持回购等。 8月22日，常熟银行盘中下跌2.08%，截至10:07，报7.53元/股，成交1.67亿元，换手率0.67%，总市 ...

Core Viewpoint - The stock of Miaokelan Duo has experienced fluctuations, with a year-to-date increase of 52.79% and a recent decline in the last 20 and 60 days, indicating potential volatility in the market [1]. Group 1: Stock Performance - On August 22, Miaokelan Duo's stock price decreased by 2.01%, reaching 27.35 CNY per share, with a trading volume of 85.76 million CNY and a turnover rate of 0.61% [1]. - The total market capitalization of Miaokelan Duo is 14.005 billion CNY [1]. - Year-to-date, the stock has risen by 52.79%, with a 1.00% increase over the last 5 trading days, but a decline of 2.39% over the last 20 days and 5.17% over the last 60 days [1]. Group 2: Financial Performance - For the period from January to June 2025, Miaokelan Duo achieved a revenue of 2.567 billion CNY, reflecting a year-on-year growth of 33.52% [2]. - The number of shareholders as of June 30, 2025, is 34,300, a decrease of 23.14% from the previous period, while the average circulating shares per person increased by 30.11% to 14,909 shares [2]. - Since its A-share listing, Miaokelan Duo has distributed a total of 368 million CNY in dividends, with no dividends paid in the last three years [2]. Group 3: Shareholder and Institutional Holdings - As of June 30, 2025, Hong Kong Central Clearing Limited has exited the list of the top ten circulating shareholders of Miaokelan Duo [2].